Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of modified SOX plus intraperitoneal high-dose paclitaxel for first-line treatment of gastric cancer with peritoneal metastasis
ChiCTR1900025984Phase 2Not yet recruiting
- Sponsor
- Cancer Center, West China Hospital, Sichuan University
- Start
- Jan 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur, oxaliplatin and paclitaxel in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Cancer Center, West China Hospital, Sichuan University. Primary endpoint: 1-year overall survival rate. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
tegafuroxaliplatinpaclitaxel
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1900025984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025984.